

Business report

Business Report	8–31
Shareholder letter	8
Summary of fiscal 2023	13
Share performance	18
Developments of investment solutions	21
Distribution developments	27
Business model and strategy	29

Shareholder letter



Gebhard Giselsbrecht, Chief Executive Officer, and Veit de Maddalena, Chairman of the Board

Dear Shareholders,

2023 was another challenging year for Bellevue Group. The below-average market performance of Bellevue's key markets in the healthcare sector once again impacted the development of our Group and tested us on both the investment and client side.

Challenging market environment for Bellevue Group persists in 2023

What made 2023 a remarkable year from an investment perspective is the continued staccato of extraneous events that impacted markets on the one hand, and the concentration of investment performance leadership with a few large cap stocks within major indexes on the other.

We have seen markets being buffeted by continued interest rate hikes (to 5.5% in the US), geopolitical tensions, the collapse of financial institutions, enthusiasm about AI and finally the reversal of interest rate and inflation expectations towards the end of the year. The «higher for longer» interest rate mantra lost weight in the second half of the year and gave way to expectations of lower interest rates towards the end of the year.

At the same time, a few mega cap tech companies largely drove the rally of major broad stock market indices in the developed world. For any active equity investor not allocated (or underallocated) to these select winners, absolute and relative underperformance was the consequence. It did not help that emerging markets and particularly China and Hong Kong continued to exhibit poor investment performance due to the deteriorating domestic economic situation as well as political concerns.

As a consequence, the healthcare sector overall saw one of the worst relative annual investment performances in 2023 with a similarly narrow investment performance leadership within the sector (by a few mega caps). In combination, these developments have been

particularly hard hitting on Bellevue Group given our focus within the healthcare sector on smaller and medium-sized growth companies and more balanced regionally weighted strategies including Asia/China.

We continue to consider the healthcare sector with its fundamental attractions and positive long-term drivers as very attractive.

We are convinced that this focus and specialization in line with our long-term oriented fundamental investment approach allows us to capture the attractive medium to long-term investment opportunities in the healthcare sector as we have shown in the past. We also continue to consider the healthcare sector with its fundamental attractions and positive long-term drivers as attractive, even if it means that we are seeing a significant impact of the above-mentioned market environment on our results today.

Financial results are reflecting the challenges

Our asset base (AuM) has decreased substantially from CHF 9.4 bn to CHF 6.9 bn (–26%). This was driven by negative absolute investment performance as well as reallocations by clients.

In line with this development, our revenues from management fees decreased by 24% to CHF 79.3 mn based on an average AuM base of around CHF 8.2 bn. Total operating income amounted to CHF 81.9 mn and were just 15% lower than the previous year mainly due to an improved net financial investment result but also due to the realization of performance fees from the private market business.

On the cost side, there was some offset from our performance-linked compensation model as a buffer. Despite continued investments into people and infrastructure we have been able to reduce operating costs by close to 5% year on year.

Nevertheless, with CHF 15.2 mn our group net profit is down 40% on a year-on-year basis. The resulting cost-income ratio of 71% is in excess of our medium-term target range of 60–65%.

We are not at all satisfied with the result we delivered for our investors and shareholders. It is and remains our ambition as a specialized asset manager to create added value for all our stakeholders.

Financial solidity as the basis for an attractive dividend policy

Our balance sheet has remained strong and free of debt. This affords us the requisite resilience to weather difficult market conditions like these and provides strategic flexibility, including the seeding of innovative investment strategies. Finally, it allows us to continue an attractive and shareholder-friendly dividend policy for investors – a dividend of CHF 1.15 is being proposed by the Board of Directors for approval at the upcoming Annual General Meeting of Bellevue Group (resulting in a dividend yield of about 4.7% based on the share price as per end of 2023).

Product range well positioned to capture growth opportunities in 2024

The current situation is an opportunity for us to take stock, refine our value proposition to investors and focus on what we do well as well as to lay the foundation for future growth with attractive investment propositions for our clients. We currently focus our internationally

Dividend 2024

(proposed)

CHF 1.15

recognized investment expertise on the three sectors healthcare, selected niches and private markets.

Our flagship products BB Biotech AG, Bellevue Medtech & Services, Bellevue Digital Health as well as the Bellevue Healthcare Trust are attractively positioned in different segments of the market and offer interesting upside potential thanks to an appealing valuation.

With the Bellevue AI Health and the Bellevue Obesity Solutions Fund, we are starting 2024 with two new strategies capturing long-term secular growth trends. The Bellevue Diversified Healthcare strategy, launched two years ago, offers a more benchmark-oriented strategy geared towards larger capitalized companies, which is performing very well in the current environment.

Our Entrepreneur investment solutions in Europe and Switzerland showed a significant revival based on a pleasing performance in 2023. We see valuation, momentum, and investment track record as being strong arguments for investments in these selected niches. For more absolute return-oriented clients our Bellevue Global Macro and Bellevue Option Premium products have exhibited attractive performances in 2023.

On the private markets side, we successfully exited one investment in 2023 despite the difficult market environment. Our well-diversified and mature portfolio of direct investments will create further opportunities for relevant exits and thus provide an attractive performance-based income (carry income). Following the promising development of our first private market vehicle Bellevue Entrepreneur Private KmGK, launched just over two and a half years ago, our ambition is to prepare the launch of a second product later in the year 2024.

Development of investment solutions

Central banks had a big impact on financial markets in 2023. Higher interest rates and signs of slowing economic activity kept investors on guard. The «higher for longer» mantra for interest rates began to resonate less during the second half of the year, ushering in strong gains for both equities and bonds. Several Bellevue strategies have already benefited from these tailwinds and others are well positioned for performance in 2024.



Continued progress made on ESG

Our commitment to environmental, social and governance (ESG) principles continues to guide our investment approach and the way we manage Bellevue Group. We believe that responsible and sustainable practices not only contribute to positive societal impact but also enhance long-term shareholder value. You will find details in our newly enhanced sustainability report.

Sustainability Report

Sustainability is and will remain an important factor in Bellevue Group's business strategy, because it is crucial to the success of our business over the long term and for creating value for all stakeholders. In order to deliver on this claim as best as possible going forward, we strengthened Bellevue's sustainability governance and organization in 2023. All relevant roles and responsibilities were reviewed at management level as well as throughout the workforce and changes were made where necessary.



Strengthening of the Executive Board of Bellevue Group

We started into the year 2024 with Gebhard Giselbrecht as the new Bellevue Group CEO. Gebhard has comprehensive international asset management experience across multiple functions. Our CFO Michael Hutter will leave Bellevue Group with Stefano Montalbano (previously Head Finance & Controlling) taking over as of March 1, 2024. The Board thanks both former CEO André Rüegg and Michael Hutter for their long tenure at Bellevue Group and their contribution to the transformation of Bellevue Group into a pure play asset manager.

To underpin and support the development of Bellevue Group going forward, the Group Executive Board will be extended with additional competencies as of March 1, 2024. Next to Gebhard Giselbrecht as CEO and Stefano Montalbano as CFO, Markus Peter will join as Head of Products & Investments and Patrick Fischli as Head of Distribution. Markus Peter and Patrick Fischli have been in management positions at Bellevue Asset Management since 2009 and have contributed substantially to the positioning of Bellevue Group as specialized asset manager.

Long-term growth prospects intact and a cautiously optimistic view on 2024

We believe in the attractive long-term growth prospects of our industry and particularly the healthcare sector within it. We are cautiously optimistic that 2024 will offer a more supportive market environment. The return to lower interest rates is constructive for the healthcare sector overall and in particular for Bellevue's investment focus on smaller and medium-sized growth stocks. The valuations for the sector and especially for smaller and medium-sized growth companies are now more attractive on both a market-relative and an absolute basis than they have been for a long time. Additionally, investor sentiment has improved significantly since last quarter of 2023 as the renewed focus is on company fundamentals rather than macro. The broadening of market leadership has been evident now for some months and has been already reflected in the performance of our strategies.

Bellevue Group is well positioned to capture the above-mentioned growth opportunities in an improving market environment leveraging our expertise, long-term investment track record and passionate employees.

However, we do not expect this to be a straight path and despite the cautious optimism, we are expecting continued volatility in the market throughout the year as inflation and rate expectations continue to adjust and recognize the potential uncertainties that may arise from

any geopolitical escalations, and the changes that will inevitably come to pass in such a busy election year.

Bellevue Group remains committed to fostering innovation, exploring new investment horizons, and maintaining transparency with our valued customers and shareholders. Rest assured that we are working hard to capture the growth opportunities ahead and we appreciate your trust and support.

The acknowledged expertise and tireless commitment of all our employees is an essential ingredient for the success of Bellevue Group. We thank our team for their vigour and commitment in these challenging times.



Veit de Maddalena
Chairman of the Board



Gebhard Giselsbrecht
Chief Executive Officer


Summary of fiscal 2023

Investor presentation



AuM reduced by around 26% compared to the previous year...

Change in AuM 2018 – 2023



Source: Bellevue Group, as at December 31, 2023


Development of assets under management

- Assets under management down 26% or around CHF 2.5 bn compared to the previous year

- Healthcare strategies represent around 88% of assets under management

...with investment performance and customer reallocations as the main drivers

Development of AuM base in 2023




Source: Bellevue Group, as at December 31, 2023

Development of assets under management

- Reduction due in equal measure to negative investment performance and client reallocations
- Gross new money won of around CHF 600 mn shows that our investment expertise continues to be sought after and appreciated

Asset Management service income declines with assets under management

Operating income from asset management activities, 2018 – 2023




Source: Bellevue Group, as at December 31, 2023

Development of income from asset management services

- Decline in revenues from asset management services of around 22% in line with the development of the average AuM base
- Average AuM base of around CHF 8.2 bn for 2023
- High proportion of recurring income (management fees)
- Only a small contribution from transaction-based fees and performance fees

Operating expenses

Cost-income ratio (CIR)
(based on operating profit)




Source: Bellevue Group, as at December 31, 2023

- Increase in cost/income ratio (CIR) to 71% due to lower earnings base
- Entrepreneurial compensation model helps to smooth out the CIR during difficult periods

Continued solid capitalised and equity-financed balance sheet

As at December 31, 2023 (consolidated)



Source: Bellevue Group, as at December 31, 2023


* Balance sheet without leverage, debt relates to operating liabilities, accruals and deferrals

- Strong balance sheet creates resilience for difficult market phases, enables the launch of innovative products and allows for an attractive dividend policy
- Reduction in goodwill & intangible assets (prior year: CHF 45 mn), due to ordinary amortisation of intangible assets

Share performance

Bellevue Group shares (BBN SW)

Bellevue Group share price performance in comparison (BBN SW)



Source: Bloomberg, Bellevue Group, as at December 31, 2023

Market capitalization

(in mn CHF)

330

as of 31.12.2023

Dividend for 2024

(in CHF)

1.15

Dividend yield

(in %)


4.7¹⁾

as of 31.12.2023

¹⁾Based on ordinary dividend of CHF 1.15 and share price on December 31, 2023

Attractive dividend of CHF 1.15 proposed for the 2023 financial year

Dividend proposal 2023 and historical development of the dividend



¹⁾ Based on the ordinary dividend and closing share price at year-end
Source: Bellevue Group, as at December 31, 2023

Proposed dividend of CHF 1.15 per share


- Attractive dividend of CHF 1.15 per share despite difficult market environment
- The payout amount is based on the Group net profit and the available surplus equity

Shareholder-friendly dividend policy confirmed

- Proposed dividend of CHF 1.15 corresponds to a payout ratio of 100% or a dividend yield of 4.7%

Shareholder base

Structure of the shareholder base as of December 31, 2023



Source: Bellevue Group, as at December 31, 2023

Attractive value creation leads to stable shareholder base

- Strong commitment of core shareholders
- Reduction in the proportion of management and employees to 11.3% (31.12.2022: 13.9%) due to personnel changes in the Group Executive Board
- Hansjörg Wyss, a long-term oriented shareholder (9.7%) won in 2020
- Very transparent shareholder base: 89% registered (2,883 shareholders)
- Shareholder-friendly dividend policy unchanged, strengthening sense of continuity


Development of investment solutions

Central banks had a big impact on financial markets in 2023. Higher interest rates and signs of slowing economic activity kept investors on guard. The «higher for longer» mantra for interest rates began to resonate less during the second half of the year, ushering in strong gains for both equities and bonds. Several Bellevue strategies have already benefited from these tailwinds and others are well positioned for performance in 2024.

2023 was quite an eventful year for global financial markets, and rather challenging for investors, too. The collapse of Silicon Valley Bank sent tremors through the market already in March. That was followed by the demise of the once-prestigious Swiss big bank Credit Suisse. Meanwhile growing investor enthusiasm for artificial intelligence (AI) and its potentially growth-boosting impact led to big gains for a few big tech companies. Statements from the US Federal Reserve that it would keep its rates high for longer to fight inflation triggered a sharp correction in the bond market from the summer on; yields on 10-year US Treasuries rose above the 5% mark for the first time since the global financial crisis in 2007. As the year ended several asset classes staged a strong rally, fueled primarily by falling inflation and the general expectation that central banks would engineer a soft landing. There was a growing conviction that interest rates had probably reached their peak, i.e. that the monetary policy reins were tight enough to bring inflation under control. This was also signaled by US Fed Fund futures, which reflect market expectations about the future course of the Fed's monetary policy.


US Fed Funds Rate (in %)

Fed Funds rate rose from 4.5% to 5.5% in 2023



US Fed Funds Rate – projected (in %)

Significant shift in fed funds futures curve over time



Source: Bloomberg, Bellevue Group, as of December 31, 2023

Broad-based equity indexes such as S&P 500 (+14.9%), the Stoxx Europe 600 (+8.9%) and the SPI (+6.1%) closed the year with good gains. The strong performance of the US market in 2023 pales when measured instead by the S&P 500 Equal Weight Index (+3.6%), which is an equal-weighted version of the cap-weighted S&P 500. At one point the «Magnificent Seven» accounted for more than 90% of the S&P 500's total return last year. Looking at sector returns at the global level, tech (+38.6%), communication services (+31.1%) and consumer cyclicals


(+21.6%) were the top performers, while healthcare (–6.8%), consumer staples (–8.9%), energy (–9.6%) and utilities (–11.3%) brought up the rear. All performance data is in CHF.

Healthcare – not the primary focus of investors in 2023, with only a few exceptions

The overall performance of healthcare stocks in 2023 was disappointing. To some extent, this is attributable to the fact that sales growth at many sector companies fell back to more normal levels after surging during the pandemic. These swings were quite pronounced at high-profile companies such as Roche, Thermo Fisher and Moderna. The steep rise in interest rates posed another big challenge, particularly for the biotech sector and digital health players. Companies that had not yet passed the breakeven point were confronted with a higher equity risk premium. Meanwhile the results of GLP-1 studies propelled the shares of the two global heavyweights Eli Lilly and Novo Nordisk to higher ground.

Specialized healthcare strategies

Absolute performance 2023, in USD



* Launched as of November 30, 2023

** Realigned as of November 30, 2023

Source: Bellevue Group, as at December 31, 2023

BB Biotech's NAV advanced 1.8% in USD during the year under review (NBI +4.6%). Its share price ended the year down 10.1% and the share premium receded to 0.9% at year-end 2023 from 12.6% a year earlier. Looking at the returns of the largest positions in the portfolio, Vertex, Intra-Cellular and Ionis made the strongest performance contributions, while Moderna, Sage Therapeutics and Incyte were the weakest. Shares of the Bellevue Healthcare Trust Fund closed the year 12.8% higher and ranked among the top-performing healthcare strategies in its peer group, reversing a period of extended volatility thanks to its strong performance in Q4.

With a gain of 5.2% for the year, Bellevue Medtech & Services outperformed the broad healthcare sector (MSCI World Healthcare +3.8%). The fund's performance took a hit after Novo Nordisk published trial results for its weight-loss drug Wegovy (GLP-1 drug). The data showed that patients who had preexisting cardiovascular disease experienced a 20%

reduction in major adverse cardiovascular events such as heart attacks and strokes after treatment with Wegovy. This news triggered a sell-off in the stocks of cardiology and orthopedics companies, and growth stocks in the diabetes space also suffered big losses. After detailed trial data was published in November indicating that GLP-1 drugs might have an only marginal impact on the business of medical technology companies in the mid to long term, these same stocks staged a rebound as the year came to end.

The Digital Health Fund's strong performance in December (+14.2%) is a good sign that digital health companies have turned the corner after a prolonged period of weakness. Digital health stocks thus ended the year well off their lows. Leading digital health companies continued to report very solid growth rates in 2023 and made considerable progress towards their strategic goals, but this positive news was overshadowed by a prolonged and steep contraction in valuations, which resulted in the fund's unsatisfactory performance of -4.1% for the year.

In August Chinese officials intensified their crackdown on corruption in the country's healthcare system. Hundreds of hospital directors and pharma managers are now under investigation. The generally good earnings announcements have shown, however, that the anti-corruption campaign has not slowed the growth of Chinese healthcare companies offering top-quality products and services. Nevertheless, the anti-corruption headlines weighed on the performance of equity strategies with emerging market exposure, including Bellevue Sustainable Healthcare (-1.4%), Bellevue Healthcare Strategy (-2.3%), Bellevue Asia Pacific Healthcare (-7.2%) and Bellevue Emerging Markets Healthcare (-7.6%).

At the J.P. Morgan Conference held in San Francisco early in 2024, several companies issued positive statements about the current fiscal year, which can often be traced to the approval and launch of relevant new products. Acquisition activity has picked up considerably, and the tepid growth outlook for the world economy could actually benefit non-cyclical sectors such as healthcare.

As a «House of Healthcare Investment Ideas», we pride ourselves on offering our clients access to mega trends as early as possible through the most efficient and effective means possible. At the end of November 2023, Bellevue launched two new funds, Bellevue AI Health and Bellevue Obesity Solutions, to specifically address the investment themes of AI healthcare and the obesity pandemic with actively managed equity funds.

Regional strategies and multi-asset solutions – a broad-based comeback


After giving up ground in 2022, both the equity and the bond market recovered in 2023. That led to positive returns for multi-asset funds as well, in contrast to 2022, when they were unable to benefit from the typical diversification effects these two asset classes offer. Compared to the US stock market, which is dominated by the «Magnificent Seven», the positive performance of Swiss and European equities in 2023 was clearly more broadly based. The equity strategies Bellevue Entrepreneur Europe Small (+17.0%) and Bellevue Sustainable Entrepreneur Europe (+10.5%) performed well, delivering double-digit returns (in EUR). Small-cap stocks in particular were back in favor. The Swiss-focused equity strategies Bellevue Entrepreneur Switzerland (+8.6%) and Bellevue Entrepreneur Swiss Small & Mid (+5.9%) also generated positive returns but were unable to match the returns of their European sister funds in CHF.

European small- and mid-cap stocks are still inexpensive and they stand to benefit from a more benign interest rate environment. Besides the future course of interest rates, there are other factors that could trigger a good performance and a valuation re-rating in the small and mid-cap space, namely 1) the slow economic recovery in China, 2) the gradual end to the global destocking trend, and 3) Europe is likely to display better economic momentum than

the US economy, where growth is leveling off, which should benefit export-oriented Swiss small and mid caps as well.

Traditional and alternative investment strategies *

Absolute performance 2023, in base currency



* Only related to liquid investment strategies (excl. Private Equity)

** Transferred to Bellevue Emerging Market Healthcare in Q1 2024

Source: Bellevue Group, as at December 31, 2023

Bellevue African Opportunities (–6.1% in USD) continued to face a challenging environment, particularly after war broke out between Hamas and Israel. Foreign investors in Egypt have been unable to repatriate their foreign assets via official foreign exchange channels for several months, so we decided to exit the Egyptian stock market.

The Bellevue Global Macro Fund ended the year with a gain of 8.5% (in EUR) thanks to the excellent performance of bond and equity markets in November and December. Every asset class in its portfolio made a positive contribution to its performance. The StarCapital Multi Income Fund closed the year with a positive return of 5.2%. The fixed income strategies Bellevue Global Income (+5.3%) and StarCapital Dynamic Bonds (+7.8%) ended the year in the green as well and outperformed the Bloomberg Global Aggregate EUR Hedged Index (+4.7%).

The Bellevue Option Premium Fund, a volatility-driven strategy, proved to be a valuable complement to a core investment portfolio. With a full-year return of 11.4% (in EUR), this product delivered a convincing performance, also in comparison with its peer group, and profiled itself as a successful diversification strategy.

Private Markets – focus on SME growth investments

Bellevue Private Markets has maintained its focus on its core business of providing growth financing to SMEs in the DACH region. Despite the volatile macroeconomic situation and geopolitical tension, attractive new investments were made during the course of 2023, and lucrative partial exits were successfully completed as well..

With adbodmer AG's exclusive group of investors and Bellevue Entrepreneur Private LPCI («LPCI») – our specialist investment company – Bellevue can muster significant financial resources and it has a broad and deep pool of entrepreneurial experience and collective know-how as well as an extensive and valuable business network at its disposal. This knowledge and capability are also appreciated and valued by both existing and potential investment targets.

Bellevue adbodmer continues to focus its deal sourcing on key themes and trends such as e-mobility, in order to capture growth opportunities with the least sensitivity to business cycles.

As an example, the adbodmer investor group and LPCI increased their stake in an Austrian SME by participating in a capital increase during the second half of 2023. Since the initial investment made in 2022, the company – which produces high-performance wires and cables for engines and power units in EV, among other products – has seen a significant improvement in its order intake. Within less than a year, additional capex was needed to expand the production capacity of the company, which is the leading high-tech supplier in this field, so it can profit even more from the market's explosive growth.

LPCI's existing portfolio companies displayed pleasing operational developments considering the challenging environment. At some companies, the pendulum swung back to more normal levels in the wake of the pandemic. Whereas inventory buildup was still widespread in 2022 (due to worries about further global supply chain disruptions) and helped to fuel sales growth, destocking activity among business customers was observed by a few portfolio companies in 2023. Declining consumer confidence was also increasingly noticed as the year progressed. However, thanks to strict cost management and flexible cost structures, most of the portfolio companies were able to cushion the impact of the above-mentioned trends. Several companies continued to grow despite the difficult environment and even managed to generate significantly higher earnings.

Bellevue adbodmer's strategic focus on companies with very solid financials and low levels of debt served the company well given the volatile environment. It also enabled some very

successful partial exits in 2023, despite the general contraction in direct private equity valuations. Adverse market headwinds have sharpened the market's focus on reliable and profitable revenue streams, which is further confirmation of our strategic focus on solidly funded champions operating in niche markets.

Distribution developments

Bellevue has a well-established client network in its three core markets Switzerland, Germany and the United Kingdom, augmented by strategic secondary markets in Austria, the Benelux and Spain. Demand in all targeted markets, especially for specialized healthcare investment vehicles, was muted in 2023 due to challenging market conditions as bond yields climbed higher and small and mid caps sold off.


International expansion and diversification

Progressive expansion of Bellevue's international activities is a core element of its business strategy. Switzerland, Germany and the United Kingdom remain Bellevue's core markets and account for the lion's share of assets under management. Operations in each core market are handled directly by a country team. The Spanish market has grown over the years to become Bellevue's fourth-largest market thanks to successful collaboration with atl Capital, a local partner. All four markets experienced asset outflows in 2023 as clients became more risk-averse.

Distribution activities in Bellevue's domestic market of Switzerland were intensified, especially in the country's French- and Italian-speaking regions. In Germany the sales and distribution team was expanded and its organizational structure modified, enabling it to address the needs of all relevant client segments efficiently and effectively. The focus of the Germany team in 2024 will be on business opportunities with savings and cooperative banks. Bellevue has a stable client base in Austria with growth potential and it is steadily building up its presence in the Benelux. In Singapore collaboration with a local partner has been fruitful. The United Kingdom has been an attractive market for BB Biotech AG and Bellevue Healthcare Trust in the past and both investment companies expect this to remain so going forward. The ramp-up of distribution activities for the Luxembourg funds in the still young Italian market has experienced some delay due to the uncertain market situation, but progress on this front should gain momentum in 2024.

In the Private Markets business, a dedicated private equity strategy was successfully launched in Switzerland in 2022. The Bellevue Entrepreneur Private Fund, which is focused on growth financing for unlisted small- and mid-sized Swiss companies, has attracted considerable interest from prominent investors. A follow-on product is at an advanced stage of planning and greater engagement of non-Swiss clients is being considered in order to extend our reach and strengthen our market position.

International reach, locally anchored



Source: Bellevue Group, as at December 31, 2023, number of employees (headcount).

Strategic growth initiatives


As part of its growth strategy, Bellevue is selectively developing new markets and client groups to enhance its operating efficiency and increase its international reach. Initial progress has been made in selected Latin American markets such as Chile and Peru. This expansion is being pursued through the recruitment of promising talent for our sales and distribution operations and through selective distribution partnerships.

Business model and strategy

A proudly independent company founded in 1993, Bellevue Group – based in Kusnacht/Switzerland – and its approximately 100 employees offer access to attractive and innovative investment ideas that generate value for investors and the company's shareholders. We employ highly qualified investment specialists with many years of experience in the areas that are relevant to us – with a particular focus on healthcare and other growth strategies. As a «House of Investment Ideas», we know that quality and innovation are vital for creating value. We are constantly exploring and exploiting promising opportunities for value growth. Our teams are guided by an entrepreneurial mindset distinguished by mutual trust and creative autonomy at all points of interaction. Our strong convictions in the investment decisions we make is why we also have an active stake in our investments – and thus in the success of the clients we serve.


At a glance

- Bellevue is a pure play, highly specialized asset manager with a distinctive focus on healthcare and other attractive growth strategies
- Expertise and innovation are what make us unique
- Creating value for clients and shareholders is our mission
- Our business model is straightforward, transparent and highly scalable
- Our financial profile is robust and low on risk
- Responsibility towards all employees, business partners and the environment is non-negotiable



Clear-cut strategy and distinctive business profile

Robust, time-tested foundation engenders trust and confidence during uncertain times




A forward- and growth-oriented strategy focused on profitability

Future growth will primarily be fueled by the investment performance of existing products, the development of interesting new products and the acquisition of new clients. We have a sound platform and clear strategy to grow on all three fronts.

Growing with our established products is a priority. Our existing products offer us substantial growth potential and the best returns. «Grow with the products» is only possible by maintaining and innovating top-quality products. Continuous investment in modern platforms and infrastructure ensures our ability to meet that goal.

A steady expansion of the underlying client base is also needed to grow with the products. Here we are pursuing various strategies to expand already strong positions in existing markets and to establish new positions in strategic secondary markets.



Reliable quality and strong innovation are the basic prerequisites for generating high value for our stakeholders.

Besides quality, innovation is another key growth driver. The development of innovative concepts for non-traditional and traditional products enables us to take full advantage of our business model's growth potential. We therefore strive to expand «Bellevue Private Markets» and in other specialized areas.

The pipeline of ideas and products for the coming years is well-filled. At the same time, existing products or services that no longer have a truly distinctive or sharp competitive edge will be re-positioned or discontinued. We are not seeking growth in and of itself, but rather sustained, quality earnings potential with an attractive cost/income ratio.